Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06515626
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-12
Brief Title:
Genetically Modified T Cells Treating Malignant Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Study to Evaluate the Safety and Efficacy of Genetically Modified T Cells in the Treatment of Malignant Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe the safety tolerability and initial effectiveness of gene modified T cell therapy in patients with malignant tumors in First Affiliated Hospital of Zhengzhou University China
Detailed Description:
The study population included subjects with malignant tumors confirmed by histopathology or cytology including non-small cell lung cancer esophageal squamous cell carcinoma gastric cancer colorectal cancer liver cancer pancreatic cancer kidney cancer cervical squamous cell carcinoma ovarian cancer breast cancer melanoma brain glioma lymphoma etc
The study is aimed to observe the safety tolerability and initial effectiveness of gene modified T cell therapy in patients with malignant tumorsTo observe Progression-Free Survival PFS and Overall survival OS after the application of gene modified T cell therapy in patients with malignant tumors and to evaluate the Disease Control Rate Disease Control Rate DCR Clinical Benefit Rate CBR Quality of Life QOLAnd explore the diversity of T cell receptors and proportion of lymphocyte subsets in subjects treated with gene-modified T cell therapy for malignant tumors changes in distribution and count immune cell function and serum cytokine levels
The study is aimed to observe the safety tolerability and initial effectiveness of gene modified T cell therapy in patients with malignant tumorsTo observe Progression-Free Survival PFS and Overall survival OS after the application of gene modified T cell therapy in patients with malignant tumors and to evaluate the Disease Control Rate Disease Control Rate DCR Clinical Benefit Rate CBR Quality of Life QOLAnd explore the diversity of T cell receptors and proportion of lymphocyte subsets in subjects treated with gene-modified T cell therapy for malignant tumors changes in distribution and count immune cell function and serum cytokine levels
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None